Schroder Investment Management Group
MYGN icon

Schroder Investment Management Group’s Myriad Genetics MYGN Stock Holding History

Schroder Investment Management Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-124,252
Closed -$2.38M – 1323
2017
Q1 		$2.38M Buy
124,252
+13,510
+12% +$239K ﹤0.01% 816
2016
Q4 		$1.85M Sell
110,742
-3,530
-3% -$63.9K ﹤0.01% 835
2016
Q3 		$2.35M Buy
114,272
+89,626
+364% +$2.27M ﹤0.01% 819
2016
Q2 		$754K Sell
24,646
-9,062
-27% -$315K ﹤0.01% 940
2016
Q1 		$1.26M Buy
+33,708
New +$1.27M ﹤0.01% 889
2015
Q1 		– Sell
-14,056
Closed -$479K – 1287
2014
Q4 		$479K Sell
14,056
-2,120,080
-99% -$75.2M ﹤0.01% 1072
2014
Q3 		$82.3M Buy
2,134,136
+294,705
+16% +$11M 0.11% 177
2014
Q2 		$71.6M Buy
1,839,431
+170,500
+10% +$6.34M 0.09% 202
2014
Q1 		$57.1M Sell
1,668,931
-235,119
-12% -$7.28M 0.06% 243
2013
Q4 		$39.9M Buy
1,904,050
+1,535,300
+416% +$38.8M 0.05% 302
2013
Q3 		$8.67M Buy
368,750
+166,350
+82% +$4.73M 0.02% 661
2013
Q2 		$5.44M Buy
+202,400
New +$5.87M 0.01% 735

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Schroder Investment Management Group's MYGN Position: Q2 2017 in Review

Schroder Investment Management Group sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 124,252 shares — an estimated $2.38M sold.

Schroder Investment Management Group first reported a position in MYGN in Q2 2013 and held it in 12 quarters. The position peaked at $82.3M in Q3 2014. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • Schroder Investment Management Group reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • Schroder Investment Management Group sold 124,252 Myriad Genetics shares in Q2 2017, an estimated $2.38M.
  • Schroder Investment Management Group first reported a position in Myriad Genetics in Q2 2013 and held it in 12 quarters.
  • Schroder Investment Management Group's Myriad Genetics position peaked at $82.3M in Q3 2014.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Schroder Investment Management Group's 13F filing for Q2 2017, filed 10 Aug 2017.